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SUMMARY
Sunitinib, a multitargeted oral tyrosine kinase inhibitor, used widely to treat solid tumors, results in hypertension in up to 47% and left ventricular dysfunction in up to 19% of treated individuals. The relative contribution of afterload toward inducing cardiac dysfunction with sunitinib treatment remains unknown. We created a preclinical model of sunitinib cardiotoxicity using engineered microtissues that exhibited cardiomyocyte death, decreases in force generation, and spontaneous beating at clinically relevant doses.
Simulated increases in afterload augmented sunitinib cardiotoxicity in both rat and human microtissues, which suggest that antihypertensive therapy may be a strategy to prevent left ventricular dysfunction in patients (6) (7) (8) . However, among sunitinib-treated patients, hypertension occurs in 11% to 43% of patients and left ventricular (LV) dysfunction in up to 19% (9) (10) (11) . These toxicities, although often manageable, can result in dose reduction or treatment interruption, which can affect oncologic outcomes.
Cardiovascular toxicity with sunitinib has been hypothesized to be a result of off-target inhibition of receptor tyrosine kinases and mitochondrial function that are important for maintaining cardiovascular homeostasis (3, 6, (12) (13) (14) , particularly during states of increased stress (15) (16) (17) (18) (19) . However, the relative contribution of each of these factors remains poorly understood. Another contributing factor that may be critical in the development of LV dysfunction during sunitinib treatment is hypertension (20) (21) (22) . More specifically, it is not clear whether hypertension unmasks LV dysfunction or actually lowers the threshold for sunitinib cardiotoxicity. We hypothesized that increased afterload augments the cardiotoxic effects of sunitinib.
Testing this hypothesis in humans would likely require substantial resources and involve ethical challenges with cohorts of patients with untreated hypertension. Current in vitro cell culture and animal models also suffer from limitations that minimize their usefulness for modeling how biomechanical influences affect sunitinib cardiotoxicity in humans (23, 24) . Thus, we used an engineered in vitro 3-dimensional (3D) cardiac microtissue (CMT) model incorporating cardiomyocytes from neonatal rats or human pluripotent stem cells that self-assemble onto polydimethylsiloxane (PDMS) pillars (25, 26) . We used this system to characterize sunitinib cardiotoxicity using metrics for cell viability, mitochondrial dysfunction, and cardiac function, and examined how these characteristics are affected by sunitinib dose, treatment duration, and the magnitude of biomechanical loading.
METHODS
CMT PLATFORM. CMT arrays were fabricated as previously described (25, 26) base to curing agent ratio) to create devices with stiff and soft pillars, respectively. Unless otherwise stated, arrays used in this study were created using a 5:1 base to curing ratio of PDMS.
MICROTISSUE SEEDING PROCEDURE. Microtissues derived from neonatal rat ventricular myocytes (NRVM) were prepared, as previously described (26) (Supplemental Appendix). CMTs, derived from human-induced pluripotent stem cell cardiomyocytes (Hu-iPS-CM) were prepared in the same manner as rat CMT with a few exceptions. Specifically, monolayers of beating Hu-iPS-CM (days 16 to 30) were detached from culture plates using TrypLE Express (Gibco, Thermo Fisher Scientific, Waltham, Massachusetts) for 7 to 10 min at 37⁰C with 5% CO 2 . Human mesenchymal stem cells (huMSC) were detached from culture plates with 0.05% Trypsin ethylenediamine tetraacetic acid (EDTA) for 5 min at 37⁰C with 5% CO 2 .
Hu-iPS-CM and huMSC were mixed to create tissues composed of 93% CM per 7% huMSC. Tissues were maintained in Roswell Park Memorial Institute medium (RPMI) þ 20% fetal bovine serum þ 100 U/ml penicillin/streptomycin þ 5 mmol/l Y27632 media for the first 24 h and then switched to RPMI þ B27 (plus insulin) þ 1% penicillin/streptomycin media, which was exchanged every 2 days. Experiments were performed on day 5 of microtissue culture. 
For active (systolic) tension measurements, fluorescence videos were captured and displacements of fluorescent beads imbedded into caps of pillars were traced in ImageJ as previously described (26) . We determined that 50 nmol/l was the threshold concentration for caspase activation for our model and observed dose-dependent increases in caspase 3/7 activation in the range of 50 nmol/l to 10 mmol/l sunitinib ( Figure 1C ). Doses >10 mmol/l were not deemed physiologically relevant to humans given that the clinically observed concentrations of sunitinib in human blood are typically 0.1 to 1.9 mmol/l.
We found that the degree of caspase activation corre- 
Increased Afterload Augments Sunitinib-Induced Cardiotoxicity before or after this time interval. Interestingly, these time points corresponded to peak caspase 3/7 activation. We also observed modest decreases in cellular (A) Dose-dependent decreases in spontaneous beating rates following 24 h of treatment with 0.1% dimethyl sulfoxide (vehicle n ¼ 10 tissues), 1 mmol/l sunitinib (n ¼ 11 tissues), or 10 mmol/l sunitinib (n ¼ 11 tissues). ****p < 0.0001 versus vehicle; *p < 0.05 1 mmol/l sunitinib versus 10 mMmol/l sunitinib. (B) Dose-dependent decreases in static (diastolic) tension generated by CMT treated for 24 h with 0.1% dimethyl sulfoxide (n ¼ 12 tissues), 1 mmol/l sunitinib (n ¼ 20 tissues), or 10 mmol/l (n ¼ 10 tissues) sunitinib. **p < 0.01 vehicle versus 1 mmol/l sunitinib, 1 mmol/l sunitinib versus 10 mmol/l sunitinib; ****p < 0.0001 vehicle versus 10 mmol/l sunitinib. Decrease in active (systolic) tension with 10 mmol/l sunitinib treatment. ****p < 0.0001 vehicle (n ¼ 4 tissues) or 1 mmol/l sunitinib (n ¼ 5 tissues) versus 10 mmol/l sunitinib (n ¼ 9 tissues). We did not observe any changes in excitation threshold (C) or maximum capture rate (D) following 24 h treatment with 0.1% dimethyl sulfoxide or 10 mmol/l sunitinib. (A, C) Data are box-and-whisker plots; median-first quartile are plotted in red, third quartile-median are plotted in green, and error bars extend from median to minimum/maximum. Abbreviation as in Figure 1 .
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myocardial toxicity associated with a given dose and duration of sunitinib.
HUMAN CMT EXHIBIT AFTERLOAD-DEPENDENT CASPASE 3/7 ACTIVATION FOLLOWING SUNITINIB
TREATMENT. We examined the responses of CMT composed of Hu-iPS-CM to sunitinib. Human CMT treated with 10 mmol/l sunitinib for 8 h exhibited significant elevations in caspase 3/7 levels ( Figure 5A ).
When we compared these responses to ones we obtained with rat CMT treated at the same concentration of sunitinib, we found that human CMT have 
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 3 , N O . 2 , 2 0 1 8
Truitt et al.
A P R I L 2 0 1 8 : 2 6 5 -7 6
Increased Afterload Augments Sunitinib-Induced Cardiotoxicity demonstrated minimal increases in caspase 3/7 levels (1.15 AE 0.08-fold vs. vehicle). Transcriptional profiling of fetal/hypertrophic genes prior to sunitinib exposure did not reveal significant expression differences based on pillar stiffness (Supplemental Table 1 Plotted are fold changes (relative to vehicle) in caspase 3/7 levels in human and rat CMT. **p < 0.01 human CMT on stiff versus soft pillars (n ¼ 2 experiments); **p < 0.001 human CMT (n ¼ 2 experiments) versus neonatal rat CMT (n ¼ 3 experiments) cultured on soft pillars. Abbreviation as in Figure 1 .
for broader preclinical analysis of cardiomyocyte toxicity for the thousands of tyrosine kinase inhibitors currently in development.
First, we confirmed our CMT model could recapitulate previously observed increases in cell death with sunitinib treatment. We detected significant increases in caspase 3/7 activation following treatment of physiological doses of sunitinib, which is consistent with reports by others (33, 34) . To our knowledge, we are the first to report that the degree of caspase 3/7 activation correlates logarithmically (log 2 ) with sunitinib dose. Additionally, we confirmed that caspase activation was time-dependent, a finding that has also been reported by others (33) . Our results also demonstrated that many of these early apoptotic cells go on to become nonviable, providing a basis for elevated troponin levels in patients (35) mmol/l) performed on human atrial muscle strips.
These differences may be explained by the fact that reduced diastolic tension likely increased diastolic length, which could conceal decreases in systolic tension due to sunitinib, particularly in experiments where we treated with low doses of sunitinib (1 mmol/l).
In addition to creating a preclinical model for sunitinib cardiotoxicity, our studies provide insights about the mechanisms of this toxicity. First, our findings of toxicity in a CMT model that is not dependent on an intact circulation support the potential for direct toxicity of sunitinib, independent of vascular effects.
These findings are consistent with the findings of Truitt et al.
